Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
Price : $35 *
At a glance
- Drugs Rapastinel (Primary)
- Indications Obsessive-compulsive disorders
- Focus Proof of concept; Therapeutic Use
- 09 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 16 Apr 2015 Treatment arms changed from 2 to1 as reported by ClinicalTrials.gov record.
- 16 Apr 2015 Planned number of patients changed from 45 to 20 as reported by ClinicalTrials.gov record.